Literature DB >> 125228

Chromatin structure in Down's syndrome.

K N Fedorova, V M Inshakova, D M Spitkovsky.   

Abstract

In the chromatin of patients with Down's syndrome, changes are shown to occur in a short-term lymphocyte culture of the human peripheral blood. Some of them are induced by the patient's blood serum and are reversible when this is replaced by normal serum. A 100-fold dilution of the blood serum taken in subjects with Down's syndrome does not produce any changes in the structure of the lymphocyte chromatin of the patients. A similar procedure with the blood serum of healthy donors resulted in a drastic activation of their lymphocyte chromatin. These experiments, and investigations on the effect produced by the blood serum on the model desoxyribonucleoprotein systems, support the suggestion that the changed state of the chromatin in subjects with Down's syndrome is caused by a complex set of components contained in the blood serum, whose degree of dissociation deviates from the normal.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 125228     DOI: 10.1007/bf00278543

Source DB:  PubMed          Journal:  Humangenetik        ISSN: 0018-7348


  5 in total

1.  Microfluorometric characterization of intracellular nucleic acids and nucleoproteins by acridine orange.

Authors:  R Rigler
Journal:  Acta Physiol Scand Suppl       Date:  1966

2.  Banding patterns of metaphase chromosomes in Down's syndrome.

Authors:  M A Ridler
Journal:  Lancet       Date:  1971-08-14       Impact factor: 79.321

3.  Constitutive heterochromatin patterns of G-group chromosomes in Down's syndrome.

Authors:  S Pathak; A K Sinha
Journal:  Humangenetik       Date:  1972

4.  Serum levels of immune globulins in health and disease: a survey.

Authors:  E R Stiehm; H H Fudenberg
Journal:  Pediatrics       Date:  1966-05       Impact factor: 7.124

5.  CHROMOSIN, A DESOXYRIBOSE NUCLEOPROTEIN COMPLEX OF THE CELL NUCLEUS.

Authors:  A E Mirsky; A W Pollister
Journal:  J Gen Physiol       Date:  1946-11-20       Impact factor: 4.086

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.